anunt

October 8, 2010 — Abbott Laboratories has withdrawn the obesity drug sibutramine (Meridia) from the market in light of clinical trial data pointing to an increased risk for stroke and myocardial infarction, the US Food and Drug Administration (FDA) announced today.
 
 
 
 

No comments:

HOME (*Revenire-Pagina la Zi)

MENU

EDITORIAL